PSMA PET-CT Offers Better Detection Rates in Recurrent PC, Study Says

PSMA PET-CT Offers Better Detection Rates in Recurrent PC, Study Says
The imaging agent 68Ga-PSMA-11 has better detection rates than 18F-fluciclovine in men with recurrent prostate cancer who have already had radical surgery to remove the prostate and whose levels of prostate-specific antigen (PSA, a marker of disease) are very low, a study says. The findings of the study, "18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial," were published in The Lancet Oncology. Whole-body positron emission tomography-computed tomography (PET-CT) scans are necessary to determine the location and extent of disease in men whose prostate cancer has returned, to select the best course of treatment. However, there is no consensus among different health authorities as to which specific PET-CT imaging agent should be used to identify suspected sites of prostate cancer recurrence in these patients. Guidelines defined by the National Comprehensive Cancer Network (NCNN) have established that 18F-fluciclovine is the most suitable imaging agent for these cases, while the European Association of Urology (EAU) recommends the use of prostate-specific membrane antigen (PSMA) PET-CT imaging agents. 18F-fluciclovine labels prostate cancer cells by exploiting their increased amino acid (the building blocks of proteins) transport, whereas PSMA PET-CT agents label prostate cancer cells containing high amounts of PSMA, a marker of disease. "Preliminary reports suggest superior detection rates of PSMA PET-CT compared with 18F-fluciclovine PET-CT. However, these imaging tests have not been compared prospectively and directly," the investigators stated. In this study, investigators reported the findings of a clinical trial des
Subscribe or to access all post and page content.